Navigation Links
Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
Date:9/13/2011

PRINCETON, N.J., Sept. 13, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b, international study of PSI-7977 and PSI-938, two nucleotide analog polymerase inhibitors for the treatment of chronic hepatitis C (HCV). The QUANTUM trial will evaluate interferon-free regimens of PSI-7977 400mg QD and PSI-938 300mg QD with and without ribavirin over 12 or 24 weeks in patients with HCV who have not been treated previously. The trial will also evaluate the use of PSI-938 monotherapy.

"We are encouraged by the early efficacy and safety data being generated with our nucleotide analogs, PSI-7977 and PSI-938," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "The QUANTUM trial is the first interferon-free, all-nucleotide study with an SVR endpoint. The ability to include all HCV genotypes was supported by data from the NUCLEAR study and the interferon free arms of the ELECTRON trial. Data from ELECTRON are expected later this year."

About the Phase 2b QUANTUM Trial This study is designed to enroll approximately 450 patients with chronic HCV of all viral genotypes who have not been treated previously. The primary endpoint of the trial will be sustained virological response (SVR24). Patients will be equally randomized across the following arms:

  • PSI-938 only
  • PSI-938 and PSI-7977
  • PSI-7977 and ribavirin
  • PSI-938, PSI-7977, and ribavirin

    • All arms will be study for both 12 and 24 weeks with a placebo control of 24 weeks.

  • Placebo for 24 weeks

    • HCV patients will be stratified by IL28B status and baseline HCV RNA to ensure balance across cohorts. Cirrhotic and non-cirrhotic patients will be enrolled in the study.

    Additional details on this and all ongoing Pharmasset sponsored trials can be found at

    SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3

    Related medicine technology :

    1. Pharmasset Announces Two-for-One Forward Stock Split
    2. Pharmasset to Present at Canaccord Genuity Growth Conference
    3. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
    4. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
    5. Pharmasset to Present at Two Upcoming Investor Conferences
    6. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
    7. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
    8. Pharmasset to Webcast an Investor Event From the EASL Meeting
    9. Pharmasset to Present at Three Upcoming Investor Conferences
    10. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
    11. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
    (Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
    (Date:5/21/2013)... 2013 U.S. spending on specialty prescription drugs ... as cancer, multiple sclerosis and rheumatoid arthritis — is ... 2015, according to a forecast released today by Express ... ) "As we see what,s on ... to act so they can continue to offer an ...
    Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
    ... N.J., Jan. 4, 2012  Ikaria, Inc., a critical care ... to address the significant needs of critically ill patients ... its Chairman and CEO, Daniel Tasse, will present at ... be given on Wednesday, January 11, 2012 at 2:00 ...
    ... 4, 2012 Express Scripts now provides services for ... & Biotech services. CuraScript, a wholly owned subsidiary of ... services, will be among a limited number of specialty ... EYLEA (aflibercept) Injection was approved by the Food and ...
    Cached Medicine Technology:Ikaria® to Present at Biotech Showcase™ 2012 2Express Scripts HealthBridge Pharma & Biotech to Provide Specialty Pharmacy and Specialty Distribution Services for EYLEA™ (aflibercept) Injection 2
    (Date:5/21/2013)... Spring is the perfect time to ... filled with whole foods to weather perfect for outdoor ... season the nutrition experts at Brilliant Nutrition highlight five ... , 1. Eating Locally, With the abundance of fresh ... and explore, spring is a great time to take ...
    (Date:5/21/2013)... Standard advice for mattress shoppers often consists ... given industry’s less than exceptional satisfaction ratings and the ... Consumer Mattress Reports sets out to revise this advice ... .” , This article addresses several components of the ... not be readily apparent to many shoppers. From prices ...
    (Date:5/21/2013)... Patients of Dr. Michael Shenk and Dr. Judd Shenk ... gum disease and would like permanent tooth replacements now have ... laser gum surgery. Gum disease must be treated prior ... of all tooth replacement options. , The Laser Assisted ... by the Food and Drug Administration (FDA) that greatly improves ...
    (Date:5/21/2013)... analogues (PGAs), drugs which lower intraocular pressure, are often ... but their use is not without risks. PGAs have ... eye color and other side effects. Now a new ... and lower eyelid drooping and other issues that can ... PLOS ONE . , Researchers from the Massachusetts Eye ...
    (Date:5/21/2013)... 2013 HealthSmart continues to grow through ... has required the hiring of new talent in several ... to announce that Dawn Powell has joined the organization ... Director of Account Management in the Central Region and ... Texas. With extensive client management, employee benefits, and product ...
    Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:Glaucoma drug can cause droopy eyelids 2Health News:New Talent Joins the HealthSmart Account Management Team 2
    ... in Desso ... Turf, BRUSSELS, Belgium, ... in a few synthetic turf,fields. The fields in question are not manufactured by ... assured that,their pitch doesn,t contain any lead., All Desso synthetic turf products ...
    ... Eating out is common while traveling, but it,s important to ... Memorial Day marks the start of the summer holiday season, ... take a vacation from your diet, cautions Elizabeth Schaub, a ... , Dining out is common when people are on holidays, ...
    ... tool for mopping up the clumps of mutant protein ... engineered a virus to make an intracellular antibody or ... the brain cells of people with Huntington,s. , Injecting ... mutant huntingtin improves their ability to move their limbs, ...
    ... in 2007but the price of phosphate fertilizers then doubled ... months from February through April 2008. The effects on ... in Sichuan Province, Chinaa major production area for nitrogen ... had already imposed dramatic new export duties on fertilizer, ...
    ... and a mathematician may seem like an unlikely duo, but ... and kept millions of sailors from getting lost at sea. ... Rockefeller University, is making history of their own. By using ... have become the first to see, in real time and ...
    ... sun-related vision damage without proper protection , , SUNDAY, May ... you,re thinking about ultraviolet (UV) protection as the weather ... the sun,s UV rays has been linked to a ... photokeratitis and corneal degenerative changes, according to the American ...
    Cached Medicine News:Health News:It's Safe to Play on Desso Synthetic Turf 2Health News:It's Safe to Play on Desso Synthetic Turf 3Health News:Don't Leave Diet Out to Lunch on Vacation 2Health News:'Intrabody' can mop up mutant protein in Huntington's disease model 2Health News:World fertilizer prices continue to soar, scientists stress need for fertilizer efficiency 2Health News:World fertilizer prices continue to soar, scientists stress need for fertilizer efficiency 3Health News:Scientists image a single HIV particle being born 2Health News:Scientists image a single HIV particle being born 3Health News:Just Like Skin, Eyes Can 'Burn' in Strong Sun 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: